Using JIMT-1 breast cancer cells, the authors reported striking differences in the cellular uptake of the inhibitors and their ability to reduce the accumulation of galectin-3 around chemically-induced disruption of intracellular vesicles of JIMT-1 breast cancer cells. This evidence concerns the gene LGALS3 and breast carcinoma.